Epizyme Quick Ratio (EPZM) starting from the second quarter 2022 to second quarter 2021, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Epizyme Inc.  (NASDAQ: EPZM)

Epizyme's Quick Ratio

EPZM's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the second quarter 2022, Quick Ratio deteriorated to 4.13 below Epizyme's average Quick Ratio.

Within Major Pharmaceutical Preparations industry 335 other companies have achieved higher Quick Ratio than Epizyme in second quarter 2022. While Quick Ratio total ranking in the second quarter 2022 has deteriorated compared to the prior quarter from 917 to 1158.

Explain Quick Ratio?
How much Cash & cash equivalents EPZM´s has?
What are EPZM´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

EPZM Quick Ratio (Jun 30 2022)
Q2		 (Mar 31 2022)
Q1		 (Dec 31 2021)
Q4		 (Sep 30 2021)
Q3		 (Jun 30 2021)
Q2
Y / Y Current Liabilities Change -14.52 % -0.1 % 16.68 % 48.1 % 52.72 %
Y / Y Cash & cash equivalent Change -40.82 % -33.19 % -52.68 % -20.94 % -24.24 %
Quick Ratio MRQ 4.13 5.13 3.91 4.95 5.97
EPZM's Total Ranking # 1158 # 917 # 516 # 1067 # 845
Seq. Current Liabilities Change -10.3 % -13.78 % 1.03 % 9.4 % 4.84 %
Seq. Cash & cash equivalent Change -27.7 % 12.98 % -20.11 % -9.31 % -18.38 %



Quick Ratio second quarter 2022 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 336
Healthcare Sector # 558
Overall Market # 1158


Quick Ratio Statistics
High Average Low
22.38 10.27 3.57
(Mar 31 2016)   (Dec 31 2013)




Financial Statements
Epizyme's Current Liabilities $ 35 Millions Visit EPZM's Balance sheet
Epizyme's Cash & cash equivalent $ 144 Millions Visit EPZM's Balance sheet
Source of EPZM's Sales Visit EPZM's Sales by Geography


Cumulative Epizyme's Quick Ratio

EPZM's Quick Ratio for the trailling 12 Months

EPZM Quick Ratio

 (Jun 30 2022)
12 Months		 (Mar 31 2022)
12 Months		 (Dec 31 2021)
12 Months		 (Sep 30 2021)
12 Months		 (Jun 30 2021)
12 Months
Y / Y Current Liabilities TTM Growth 10.09 % 26.03 % 41.85 % 34.24 % 23.08 %
Y / Y Cash & cash equivalent TTM Growth -37.97 % -33.95 % -30.4 % -16.3 % -12.82 %
Quick Ratio TTM 4.53 4.96 5.54 6.96 8.04
Total Ranking TTM # 5151 # 5066 # 4881 # 479 # 4909
Seq. Current Liabilities TTM Growth -3.5 % -0.02 % 3.95 % 9.76 % 10.48 %
Seq. Cash & cash equivalent TTM Growth -11.83 % -10.54 % -17.3 % -4.9 % -6.12 %

Quick ratio ranking by company, industry and sector >> Back to EPZM Financial Strength Comparisons >> Go to Compare EPZM Quick Ratio to its Competitors

On the trailing twelve months basis In spite of the year on year decrease in EPZM's Current Liabilities to $34.95 millions, cumulative Quick Ratio to 4.53 below the EPZM average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 584 other companies have achieved higher Quick Ratio than Epizyme. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2022 from 5066 to 5151.

Explain Quick Ratio?
How much Cash & cash equivalents EPZM´s has?
What are EPZM´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 585
Healthcare Sector # 1165
Within the Market # 5151


trailing twelve months Quick Ratio Statistics
High Average Low
16.65 10.64 4.53
(Sep 30 2016)   (Jun 30 2022)




Companies with similar Quick Ratio in the quarter ending Jun 30 2022, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2022 MRQ Cash & cash equivalentJun 30 2022 MRQ Current Liabilities
Zevra Therapeutics Inc   11.31 $ 80.978  Millions$ 7.159  Millions
Corcept Therapeutics Inc  11.22 $ 370.086  Millions$ 32.990  Millions
Alzamend Neuro Inc   11.21 $ 11.527  Millions$ 1.029  Millions
Relmada Therapeutics Inc  11.20 $ 211.955  Millions$ 18.921  Millions
Cytokinetics Incorporated  11.15 $ 586.026  Millions$ 52.540  Millions
Tonix Pharmaceuticals Holding Corp   11.12 $ 176.978  Millions$ 15.909  Millions
Pulmatrix Inc   11.04 $ 43.058  Millions$ 3.899  Millions
Q32 Bio Inc   10.88 $ 225.523  Millions$ 20.734  Millions
Citius Pharmaceuticals Inc   10.78 $ 48.082  Millions$ 4.461  Millions
Oncternal Therapeutics Inc   10.71 $ 78.900  Millions$ 7.368  Millions
Pepgen Inc   10.63 $ 218.817  Millions$ 20.577  Millions
Point Biopharma Global Inc   10.61 $ 199.433  Millions$ 18.797  Millions
Damora Therapeutics Inc   10.55 $ 79.026  Millions$ 7.488  Millions
Virpax Pharmaceuticals Inc   10.49 $ 26.061  Millions$ 2.483  Millions
Sinovac Biotech Ltd  10.37 $ 11,320.946  Millions$ 1,091.635  Millions
Arcutis Biotherapeutics Inc   10.27 $ 282.169  Millions$ 27.482  Millions
Sol gel Technologies Ltd   10.25 $ 35.806  Millions$ 3.493  Millions
Quantum Cyber N v   10.17 $ 43.148  Millions$ 4.243  Millions
Atreca inc   10.03 $ 101.732  Millions$ 10.142  Millions
Neuphoria Therapeutics Inc   10.00 $ 33.565  Millions$ 3.356  Millions
Mustang Bio inc   10.00 $ 107.369  Millions$ 10.739  Millions
Evoke Pharma Inc   9.94 $ 13.451  Millions$ 1.353  Millions
Mirati Therapeutics Inc   9.91 $ 1,181.328  Millions$ 119.147  Millions
Moleculin Biotech Inc   9.90 $ 57.999  Millions$ 5.859  Millions
Phathom Pharmaceuticals Inc   9.84 $ 207.392  Millions$ 21.075  Millions
REST EZ Inc.  9.83 $ 0.410  Millions$ 0.042  Millions
Catalyst Pharmaceuticals Inc   9.82 $ 220.788  Millions$ 22.488  Millions
Aprea Therapeutics Inc   9.79 $ 39.062  Millions$ 3.990  Millions
Essa Pharma inc   9.73 $ 67.920  Millions$ 6.979  Millions
Cns Pharmaceuticals Inc   9.70 $ 8.959  Millions$ 0.924  Millions

Date modified: 2026-09-08T15:10:41+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.